Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…

Background Glioblastoma is associated with a poor prognosis in the elderly. Survival has
been shown to increase among patients 70 years of age or younger when temozolomide …

Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary
potency and breadth have recently been described. In humanized mice, combinations …

Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy,
followed by radiation plus concomitant and adjuvant temozolomide. The treatment of …

The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine
development 1 , 2 . Antigens derived from natural HIV-1 sequences have elicited only a limited …

Purpose Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has
increased survival in patients with glioblastoma multiforme (GBM). However, few options are …

BACKGROUND Venous thromboembolism (VTE) frequently complicates the course of
patients with cancer, and there is evidence to suggest that patients with brain tumors are at …

Preclinical studies of viral vector–based HIV-1 vaccine candidates have previously shown
partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this …

Background Survival outcomes for patients with glioblastoma remain poor, particularly for
patients with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter…

Background This phase I/II trial evaluated the maximum tolerated dose (MTD) and
pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as …